Results 251 to 260 of about 90,988 (285)

Mitomycin-C in Congenital Glaucoma

Ophthalmic Surgery, Lasers and Imaging Retina, 1997
* BACKGROUND AND OBJECTIVE: To evaluate the adjunctive use of mitomycin-C (MMC) during trabeculotomy and trabeculectomy for eyes with highrisk congenital glaucoma. * PATIENTS AND METHODS: A prospective, randomized, double-blind study was performed to compare the effect of a single, 4-minute intraoperative exposure to 0.2 mg/ml (group 1) or 0 ...
H C, Agarwal, N N, Sood, R, Sihota, L, Sanga, S G, Honavar   +4 more
openaire   +2 more sources

Dacryocystorhinostomy with Intraoperative Mitomycin C

Ophthalmology, 1997
To observe the effect of intraoperative mitomycin C on the size of the osteotomy site after dacryocystorhinostomy.:A total of 15 eyes of 14 patients diagnosed with primary acquired nasolacrimal duct obstruction were assigned randomly to either a mitomycin C group or a control group.
S C, Kao, C L, Liao, J H, Tseng, M S, Chen, P K, Hou   +4 more
openaire   +2 more sources

Renal toxicity of mitomycin-C

American Journal of Clinical Oncology, 1984
The clinical spectrum and the pathological findings of renal toxicity in four patients treated with mitomycin-C are described. Our experience and evidence in the literature indicates that the renal impairment appears to be total-dose-related, with most patients developing renal symptoms after receiving at least 60 mg of mitomycin-C.
T S, Ravikumar, R, Sibley, K, Reed, T B, Grage   +3 more
openaire   +2 more sources

Mitomycin C.

Cancer chemotherapy and biological response modifiers, 1994
In conclusion, recent work has highlighted the fact that NSCLCs have elevated levels of NQO1 activity and that such an increase represents an excellent target for therapeutic exploitation. The 5-year survival rate seen with lung cancer is dismal and there is a high number of cancer deaths associated with this disease each year.
N W, Gibson, D, Ross
openaire   +1 more source

Mitomycin C in Photorefractive Keratectomy

Journal of Refractive Surgery, 2009
Purpose: To evaluate the outcome of primary or retreatment photorefractive keratectomy (PRK) or photo-therapeutic keratectomy (PTK) with mitomycin C (MMC) 0.02% applied prophylactically intraoperatively for the prevention of haze and regression in cases of significant haze and regression after primary PRK, due to previous ...
Ashraf, Shalaby, Geoffrey B, Kaye, Howard V, Gimbel   +2 more
openaire   +2 more sources

Pharmacokinetics of intraperitoneal mitomycin C

Surgical Oncology Clinics of North America, 2003
The favorable pharmacokinetics of MMC, used during intraperitoneal chemotherapy, has been reported in several studies [11-19]. A major safety issue in studies using intraperitoneal chemotherapy perfusion is the resulting systemic drug exposure. The AUCplasma is determined by the dose, the clearance, and the fraction absorbed from the peritoneal cavity.
S, van Ruth, V J, Verwaal, F A, Zoetmulder   +2 more
openaire   +2 more sources

Intraoperative Mitomycin C in Dacryocystorhinostomy

Ophthalmic Plastic and Reconstructive Surgery, 2001
To assess the efficacy of intraoperative mitomycin C (MMC) in external dacryocystorhinostomy (EXT-DCR).Forty-six cases (50 lacrimal drainage systems [LDS]) with nasolacrimal duct obstruction were randomized into three groups. In the control group, a standard EXT-DCR procedure was performed. In the two MMC groups, a piece of cotton soaked with 0.2 mg/ml
Y A, You, C T, Fang
openaire   +2 more sources

Reductive activation of mitomycin C

Biochemistry, 1988
Mitomycin C, an antitumor antibiotic, is known to require reductive activation in order to function as an alkylating agent. In this work reduction has been carried out by using radiolytically produced formate radicals that reduce mitomycin C to its semiquinone in a clean rapid one-electron reaction.
B M, Hoey, J, Butler, A J, Swallow
openaire   +2 more sources

Mitomycin C

Cold Spring Harbor Protocols, 2006
  +4 more sources

Mitomycin C

Reactions, 1985
openaire   +1 more source